Guided Therapeutics (OTCMKTS:GTHP) and Cellectar Biosciences (NASDAQ:CLRB) Head to Head Survey

Guided Therapeutics (OTCMKTS:GTHP) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Earnings and Valuation

This table compares Guided Therapeutics and Cellectar Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guided Therapeutics	$770,000.00	25.42	-$3.20 million	($0.04)	-5.07
Cellectar Biosciences	N/A	N/A	-$21.79 million	($6.66)	-0.33

Guided Therapeutics has higher revenue and earnings than Cellectar Biosciences. Guided Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Guided Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

Institutional & Insider Ownership

9.7% of Guided Therapeutics shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 66.8% of Guided Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for Guided Therapeutics and Cellectar Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	0.00
Cellectar Biosciences	1	0	3	0	2.50

Cellectar Biosciences has a consensus price target of $11.00, indicating a potential upside of 393.27%. Given Cellectar Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than Guided Therapeutics.

Profitability

This table compares Guided Therapeutics and Cellectar Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-274.24%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Summary

Guided Therapeutics beats Cellectar Biosciences on 6 of the 11 factors compared between the two stocks.

About Guided Therapeutics

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.

About Cellectar Biosciences

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.